With inflation signals mixed across regions, policy makers weighing their next moves and growth momentum differing sharply from one economy to another, many investors are looking for stocks that pair earnings growth potential with balance sheet strength. The Healthy high growth potential screener focuses on companies that analysts expect to grow earnings over the next 3 years while staying in acceptable financial shape, which can be appealing when bond yields, export demand and consumer spending all send conflicting signals. In this article, you will see 3 stocks from this screener that stand out on those criteria.

Remitly Global (RELY)

Overview: Remitly Global is a Seattle based fintech that lets people send money across borders through a mobile app and website, focusing on digital remittances and related financial services for customers in the United States, Canada and many other countries.

Operations: Remitly Global generates about US$1.7b in revenue primarily from data processing services, with around US$1.1b from the United States, US$168m from Canada and US$415m from the rest of the world.

Market Cap: US$5.3b

Remitly Global is attracting attention because it sits at the intersection of rising cross border payments, digital wallets and AI driven fraud prevention. It is already profitable, with earnings growth forecasts reportedly well above 20%. Analysts report that revenue and earnings are expected to grow faster than the broader US market. Recent licenses in the UAE and expanded WhatsApp Send functionality show how the company is pushing deeper into key remittance corridors. At the same time, a rich P/E multiple, reliance on external borrowing and regulatory scrutiny around stablecoins mean execution risk is real. To understand how these strengths and vulnerabilities fit together, it is necessary to look beyond headline growth rates and recent share buybacks.

Remitly Global’s rapid cross border expansion and AI driven fraud tools are only half the story. To see how growth expectations compare with potential execution pitfalls, review the analyst forecasts for Remitly Global

Everpure (P)

Overview: Everpure is a data storage and management company that provides all flash storage systems, subscription software and cloud based services that help businesses run databases, applications, virtual machines and AI workloads efficiently across on premises and public cloud environments.

Operations: Everpure generates about US$3.9b in revenue from computer storage devices, with roughly US$2.7b from the United States and US$1.3b from the rest of the world.

Market Cap: US$23.5b

Everpure operates in a crowded AI infrastructure space and combines specialist flash storage hardware, software such as Portworx and Evergreen, and AI focused offerings such as Data Stream and Data Intelligence. The company has remained profitable with rising net margins and strong earnings momentum. Forecast earnings growth above 20% a year and revenue growth projected ahead of the wider US market have attracted analyst attention, but a very high P/E and reliance on external borrowing mean the stock carries risks. Recent guidance upgrades, product partnerships with NVIDIA, Veeam and Supermicro, and activist interest from Jana Partners indicate that many investors are still assessing how to value the business.

Everpure’s AI storage story, rising margins and brisk earnings forecasts are only part of the picture, and the analyst forecasts for Everpure could reveal whether current enthusiasm masks a crucial risk investors are missing

Celcuity (CELC)

Overview: Celcuity is a clinical stage biotech company developing targeted therapies for solid tumors, led by gedatolisib, a drug that blocks the PI3K and mTOR pathways in hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. After years focused on trials, Celcuity is now shifting toward commercialization following recent FDA approvals for its breast cancer treatment under the brand name REVTORPYK.

Market Cap: US$4.5b

Celcuity is attracting interest because REVTORPYK has now moved from trial data to full FDA approval in a clearly defined breast cancer population, with analysts pointing to factors such as efficacy, a relatively clean safety profile and premium pricing that could support meaningful revenue once the delayed US launch gets underway. At the same time, the company is still loss making, carries high valuation ratios and leans on external funding, so future earnings depend heavily on how quickly physicians adopt the drug and how payers respond. With further VIKTORIA trial readouts, potential label expansion into PIK3CA mutant disease and a second tumor type in prostate cancer all under consideration, Celcuity presents a high growth story in which the balance between clinical progress, execution risk and current market expectations is important.

Celcuity’s REVTORPYK story is moving from lab to real patients, but the market may not fully appreciate how earnings projections and rich valuation intersect, so the analyst forecasts for Celcuity could surface the twist that changes the whole thesis

The three stocks covered here are just a starting point. The full Healthy high growth potential screen on Simply Wall St surfaced 253 more companies with similarly strong growth expectations and balance sheet profiles that could fit different risk and sector preferences, all accessible through the Healthy high growth potential screener. Use Simply Wall St to identify, analyze and filter for the exact catalysts and narratives that matter to you so you can focus on the highest conviction opportunities instead of sifting through the entire market on your own.

Take Control of Your Investment Journey

If Everpure or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Momentum Flies?

Markets move fast and the strongest ideas do not stay under the radar for long. Spot fresh breakouts before the crowd, while it matters, and get in early.

• Target steadier growth potential with a curated list of solid balance sheet and fundamentals (47 results) so you are not caught chasing momentum while weaker balance sheets start dropping.
• Ride potential income momentum by scanning 8 dividend fortresses before yields get compressed and the best opportunities are flying out of reach. Consider acting while the terms still fit your criteria.
• Position ahead of possible infrastructure breakouts by checking 35 power grid technology and infrastructure stocks while they are still under the radar for now, instead of reacting after any move is already running.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.